Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

GlobeNewswire September 27, 2021

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021

GlobeNewswire September 23, 2021

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 1, 2021

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

GlobeNewswire August 18, 2021

Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

GlobeNewswire August 9, 2021

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

PR Newswire August 5, 2021

Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague

GlobeNewswire August 4, 2021

Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

GlobeNewswire August 3, 2021

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2021

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

GlobeNewswire August 2, 2021

Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million

GlobeNewswire June 29, 2021

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)

GlobeNewswire June 16, 2021

Paratek Appoints Minnie Baylor-Henry to Company's Board of Directors

GlobeNewswire June 14, 2021

Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus

GlobeNewswire June 10, 2021

Crestone Joins Antimicrobials Working Group

PR Newswire June 8, 2021

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2021

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

GlobeNewswire June 1, 2021

Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021

Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement

GlobeNewswire May 17, 2021